NovaBridge Biosciences American
$1.77 $0.00 (+0.00%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jun 29
The stock moved +20.7% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jun 29 -
Jun 11
From its Feb 6 high, the share price fell 60%.
Peak close $3.70 on Feb 6; trough close $1.47 on Jun 11. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -60% -
Mar 5
The stock moved +17.0% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 5
The story updates itself as events post · The wolf reports; you decide
Snapshot
About NovaBridge Biosciences American
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.